Drug Classification · Questions 1–6
Identify the pharmacological class or categorical label for each drug or concept. Vocabulary preparation is sufficient to answer every question in this section.
Question 1
Which of the following pharmacokinetic terms refers to the fraction of an administered drug dose that reaches the systemic circulation in an unchanged, active form?
Correct Answer
C — Bioavailability
Rationale
Bioavailability is defined as the fraction of an administered dose that reaches the systemic circulation in an active form and is available to produce a pharmacological effect. It is expressed as a value between 0 and 1, or as a percentage. Intravenous administration gives a bioavailability of 1.0 by definition. All other routes give bioavailability less than 1.0 due to absorption barriers and first-pass metabolism. Half-life is the time for plasma concentration to fall by half. Volume of distribution describes the apparent space in which a drug is distributed. Clearance is the volume of plasma cleared of drug per unit time.
Question 2
Which of the following pharmacokinetic parameters describes the theoretical volume of fluid that would be required to contain the total amount of drug in the body at the same concentration observed in the plasma?
Correct Answer
A — Volume of distribution
Rationale
The volume of distribution is an apparent rather than a real anatomical volume — it reflects how extensively a drug distributes out of the plasma and into tissues. A drug that stays largely in the bloodstream has a small volume of distribution close to the plasma volume. A drug that distributes widely into tissues has a large volume of distribution that can far exceed total body volume, because most of the drug is in tissues and only a small fraction remains in the plasma. Clearance is the volume of plasma cleared of drug per unit time. Bioavailability is the fraction reaching systemic circulation. Half-life is the time for plasma concentration to fall by half.
Question 3
A drug undergoes glucuronidation in the liver, in which a glucuronic acid molecule is attached to the drug to form a highly water-soluble conjugate that is readily excreted in urine. This reaction is classified as which of the following?
Correct Answer
D — Phase Two metabolism
Rationale
Phase Two reactions involve the conjugation of a drug or its Phase One metabolite with an endogenous polar molecule — such as glucuronic acid, sulfate, acetate, or glutathione — to produce a highly water-soluble compound that is efficiently excreted. Glucuronidation is the most common Phase Two reaction. These conjugates are generally pharmacologically inactive and readily eliminated by the kidneys or bile. Phase One reactions introduce or expose a polar functional group through oxidation, reduction, or hydrolysis, preparing the molecule for conjugation. Biliary excretion and renal tubular secretion are elimination processes, not metabolic reactions.
Question 4
After oral ingestion, a drug is absorbed from the gastrointestinal tract and enters the portal circulation, where it passes through the liver before reaching the systemic bloodstream. A large fraction of the drug is metabolized during this transit, substantially reducing the amount that reaches its target. This phenomenon is best described by which of the following terms?
Correct Answer
B — First-pass effect
Rationale
The first-pass effect — also called presystemic hepatic metabolism — refers to the metabolic extraction of drug by the liver during the initial passage of orally absorbed drug through the portal circulation. Drugs subject to high first-pass extraction have low oral bioavailability even when they are well absorbed from the gut, because the liver removes much of the absorbed dose before it can reach the systemic circulation. This is why some drugs are given by routes that bypass the portal circulation — sublingually, transdermally, or by inhalation. Renal clearance and active tubular secretion are renal elimination processes. Protein binding is a distribution phenomenon.
Question 5
When a drug is given at a fixed dose and fixed dosing interval, plasma drug concentration rises with each successive dose until the rate of drug administration equals the rate of elimination. The plateau concentration at which this equilibrium is reached is referred to as which of the following?
Correct Answer
C — Steady state
Rationale
Steady state is the condition in which the amount of drug administered in each dosing interval exactly replaces the amount eliminated during that interval, producing a stable average plasma concentration. For drugs following first-order elimination kinetics, steady state is reached after approximately four to five half-lives of the drug, regardless of the dose or dosing interval. Doubling the dose raises the steady-state concentration but does not shorten the time to reach it. Peak concentration refers to the highest concentration after a single dose. Trough concentration refers to the lowest concentration at the end of a dosing interval. Maximum tolerated concentration is a safety parameter, not a steady-state concept.
Question 6
A drug is administered in an inactive form and must be converted by hepatic enzymes to its pharmacologically active metabolite before it can produce a therapeutic effect. This type of drug is classified as which of the following?
Correct Answer
A — Prodrug
Rationale
A prodrug is a pharmacologically inactive compound that is converted in the body — most commonly by hepatic enzymes — to an active metabolite that produces the desired therapeutic effect. Prodrug design is used to improve oral bioavailability, stability, or tolerability. Codeine and clopidogrel are classic prodrugs requiring metabolic activation. Biologics are large-molecule drugs produced by living cell systems. Semisynthetic drugs are made by chemically modifying natural compounds — this describes the manufacturing origin, not the pharmacological activity at the time of administration.
Core Pharmacology · Questions 7–14
Apply your understanding of drug mechanisms, pharmacokinetics, and adverse effects. Each question requires one reasoning step.
Question 7
A drug given intravenously at a dose of 10 mg achieves the target plasma concentration. The same drug given orally has a bioavailability of 25% due to extensive first-pass hepatic metabolism. Which of the following oral doses would be required to achieve the same plasma exposure as the 10 mg intravenous dose?
Correct Answer
B — 40 mg, because only 25% of the oral dose reaches the systemic circulation
Rationale
When oral bioavailability is 25%, only one quarter of the administered dose reaches the systemic circulation. To deliver the same systemic exposure as 10 mg given intravenously, the oral dose must be divided by the bioavailability fraction: 10 mg divided by 0.25 equals 40 mg. This calculation explains why oral doses are frequently much higher than intravenous doses for drugs with extensive first-pass metabolism — the extra drug given orally compensates for hepatic extraction. First-pass metabolism does not amplify drug activity; it reduces the amount of active drug that survives to reach the circulation.
Question 8
A highly lipophilic drug distributes extensively into adipose tissue and other peripheral compartments, leaving very little drug in the plasma at any given time. Which of the following best predicts the consequence of this distribution pattern for attempts to remove the drug by hemodialysis in a patient with an overdose?
Correct Answer
D — Hemodialysis will be ineffective because most of the drug is sequestered in tissues, not in the plasma being filtered
Rationale
Hemodialysis removes drug from the plasma compartment. A drug with a large volume of distribution has most of its total body burden in tissues rather than plasma — the plasma concentration at any given moment represents only a small fraction of the drug in the body. Filtering plasma therefore removes very little of the total drug load, making dialysis ineffective for overdose management. Drugs amenable to dialysis removal are those with small volumes of distribution, low protein binding, and water solubility — all of which keep drug in the plasma where it can be filtered. Lipophilicity drives tissue distribution and a large volume of distribution, making dialysis less useful, not more.
Question 9
A drug is eliminated primarily by renal excretion with no significant hepatic metabolism. A patient with severe chronic kidney disease begins taking this drug at the standard dose and dosing interval. Compared with a patient who has normal renal function, which of the following changes in pharmacokinetics is most expected in this patient?
Correct Answer
A — Prolonged half-life and accumulation of drug to higher steady-state concentrations
Rationale
When renal clearance is reduced by kidney disease, the drug is eliminated more slowly from the body. Because half-life is inversely related to clearance, reduced renal clearance prolongs the half-life. At the same dose and dosing interval, the drug accumulates to a higher steady-state concentration than in a patient with normal renal function, increasing the risk of dose-dependent toxicity. The clinical response is to reduce the dose, lengthen the dosing interval, or both. The liver does not meaningfully compensate for reduced renal clearance of drugs that are not hepatically metabolized. Renal impairment does not reduce gastrointestinal absorption or oral bioavailability.
Question 10
A drug has a half-life of 2 hours. If it is dosed every 8 hours, which of the following best describes what happens to plasma drug concentration between doses?
Correct Answer
C — Plasma concentration falls substantially between doses, potentially dropping below the therapeutic range
Rationale
With a half-life of 2 hours and a dosing interval of 8 hours, four half-lives elapse between doses. After four half-lives, plasma concentration falls to one-sixteenth of the peak concentration. For a drug with a narrow therapeutic range, this degree of fluctuation would likely result in subtherapeutic concentrations for much of the dosing interval, reducing efficacy. Drugs with short half-lives relative to the desired dosing interval require either more frequent dosing or extended-release formulations to maintain therapeutic concentrations throughout the day. Plasma concentration does not remain constant between doses — it follows an exponential decline governed by the half-life.
Question 11
A patient requires immediate therapeutic drug concentrations of an antiarrhythmic with a half-life of 36 hours. At the standard maintenance dose, it would take approximately six to seven days to reach steady-state concentrations. Which of the following pharmacokinetic strategies is most appropriate to achieve rapid therapeutic concentrations in this patient?
Correct Answer
B — Administer a loading dose larger than the maintenance dose to rapidly achieve the target concentration
Rationale
A loading dose is a larger-than-maintenance initial dose designed to rapidly fill the drug's volume of distribution and bring plasma concentrations into the therapeutic range without waiting for the slow accumulation that would occur with maintenance dosing alone. After the loading dose achieves the target concentration, regular maintenance doses replace the drug eliminated between each dosing interval. Loading doses are particularly valuable for drugs with long half-lives where waiting for steady state would take days, and where immediate therapy is clinically necessary. Doubling the dosing frequency does not bypass the time-to-steady-state problem — it still takes approximately five half-lives to reach steady state.
Question 12
A patient with cirrhosis is prescribed an oral drug that normally undergoes 70% first-pass hepatic extraction in patients with healthy liver function. Compared with the standard oral dose in a patient with normal hepatic function, which of the following changes in the drug's pharmacokinetics is most expected in this patient?
Correct Answer
D — Increased oral bioavailability due to reduced first-pass hepatic extraction
Rationale
In cirrhosis, reduced hepatic mass and portosystemic shunting diminish the liver's ability to extract and metabolize drug during first-pass transit. For a drug that is normally heavily extracted by the liver, this impairment allows a larger fraction of the absorbed dose to pass through to the systemic circulation, dramatically increasing oral bioavailability and resulting in higher-than-expected plasma concentrations at standard doses. This is why drugs with high first-pass extraction — such as propranolol, morphine, and lidocaine — must be dosed more cautiously in patients with significant liver disease. Gastrointestinal absorption and renal clearance are unaffected by hepatic impairment in this context.
Question 13
A drug is 95% bound to albumin in the plasma of healthy patients, with only 5% existing as free drug. A patient with severe liver disease has markedly reduced albumin synthesis and a serum albumin of 1.8 g/dL. At the same total plasma drug concentration, which of the following best describes the expected effect on free drug concentration and pharmacological activity in this patient?
Correct Answer
A — Free drug concentration increases, amplifying pharmacological effect and toxicity risk
Rationale
Only the free (unbound) fraction of a drug is pharmacologically active, can cross cell membranes, and is available for metabolism and elimination. When albumin is reduced, a larger proportion of the total drug is unbound. At the same measured total plasma concentration, the free drug concentration — and therefore the pharmacological effect — is substantially higher than in a patient with normal albumin. This is clinically important for highly protein-bound drugs with narrow therapeutic indices: the total plasma concentration may appear "therapeutic" while the free fraction is actually toxic. Albumin synthesis by the liver decreases in liver disease; it does not produce compensatory binding proteins.
Question 14
A physician starts a patient on a drug with a half-life of 12 hours. The patient asks when the drug will reach its full steady-state effect. The physician correctly explains that regardless of the dose selected, steady-state plasma concentrations are reached after approximately how many half-lives?
Correct Answer
C — Four to five half-lives
Rationale
For drugs following first-order elimination kinetics, approximately 97% of steady-state concentration is reached after five half-lives. This relationship is a fixed property of first-order kinetics and does not change with dose — a higher dose reaches a higher steady-state concentration, but the time to reach that plateau is the same. For the drug in this question with a 12-hour half-life, steady state is reached in approximately 48 to 60 hours. This principle has direct clinical implications: increasing the dose of a drug to speed up its effect will not bring steady state sooner — it will only raise the eventual plateau. A loading dose is the correct strategy when rapid achievement of therapeutic concentrations is needed.
Clinical Correlations · Questions 15–18
Apply pharmacological knowledge to clinical scenarios. Each vignette presents a patient situation; the question tests mechanism of action or drug selection.
Question 15
A 45-year-old woman with cancer-related pain is well controlled on intravenous morphine at 5 mg every 4 hours. Her care team transitions her to oral morphine at the same dose of 5 mg every 4 hours, and she immediately reports inadequate pain relief. Her physician explains that a substantially higher oral dose will be needed to achieve equivalent analgesia. Which of the following pharmacokinetic mechanisms best explains why the same dose produces a weaker effect by the oral route?
Correct Answer
B — Oral morphine undergoes extensive first-pass hepatic metabolism, reducing systemic bioavailability to approximately 20 to 40%
Rationale
Morphine absorbed from the gastrointestinal tract enters the portal circulation and passes through the liver before reaching the systemic bloodstream. The liver extracts and metabolizes a large fraction of this absorbed drug on the first pass, leaving only 20 to 40% of the oral dose available to produce analgesia. Intravenous morphine bypasses hepatic extraction entirely, achieving 100% bioavailability. Dose conversion from intravenous to oral morphine therefore requires approximately a three-fold increase in dose to compensate for first-pass loss. The route of administration does not alter protein binding or renal clearance.
Question 16
A 68-year-old man with an estimated glomerular filtration rate of 22 mL/min per 1.73 m² is hospitalized for a gram-negative bacterial infection and started on gentamicin at the standard adult dose and dosing interval. Three days later he develops worsening renal function and signs of gentamicin toxicity. Gentamicin is eliminated almost entirely by renal filtration with no hepatic metabolism. Which of the following best explains why this patient developed toxicity at a dose that would be safe in a patient with normal renal function?
Correct Answer
D — Reduced renal clearance prolongs gentamicin half-life, causing accumulation to toxic concentrations at standard dosing
Rationale
Gentamicin depends entirely on renal filtration for elimination. When glomerular filtration rate is severely reduced, gentamicin is cleared much more slowly than in a patient with normal renal function. The prolonged half-life means that each dose is not eliminated before the next dose is given, so the drug accumulates with successive doses to concentrations well above those achieved in a patient with normal renal function. Gentamicin toxicity — nephrotoxicity and ototoxicity — is concentration-dependent, making accumulation in renal impairment a predictable and preventable cause of harm. Dose reduction, extended dosing intervals, and therapeutic drug monitoring are required when aminoglycosides are used in patients with reduced renal function.
Question 17
A 54-year-old man with alcoholic cirrhosis and portal hypertension is started on propranolol to reduce the risk of variceal bleeding. He develops marked bradycardia and hypotension at a dose that is well tolerated by most patients. Propranolol normally undergoes approximately 70% first-pass hepatic extraction after oral administration. Which of the following best explains his exaggerated response?
Correct Answer
A — Cirrhosis reduces first-pass extraction, greatly increasing the oral bioavailability of propranolol and producing higher-than-expected plasma concentrations
Rationale
In healthy patients, approximately 70% of orally absorbed propranolol is extracted and metabolized by the liver on first pass, giving an oral bioavailability of roughly 30%. In cirrhosis, reduced hepatic mass and portosystemic shunting impair this first-pass extraction, allowing a much larger fraction of the absorbed dose to reach the systemic circulation. The result is substantially higher plasma concentrations at the same oral dose — producing the exaggerated bradycardia and hypotension seen in this patient. This pharmacokinetic effect is the reason propranolol and other high-first-pass drugs must be started at reduced doses in patients with severe liver disease.
Question 18
A 72-year-old woman with advanced heart failure and hepatic congestion has a serum albumin of 2.1 g/dL. She is started on digoxin at a standard dose and develops signs of toxicity — nausea, visual disturbances, and bradycardia — despite a measured total digoxin plasma concentration within the usual reference range. Digoxin is approximately 25% bound to plasma proteins in healthy patients. Which of the following best explains why she developed toxicity despite an apparently therapeutic total drug level?
Correct Answer
C — Her reduced albumin increased the free fraction of digoxin, raising pharmacologically active drug concentrations despite a normal total level
Rationale
Standard drug concentration assays measure total drug — bound plus free. Only the free fraction is pharmacologically active. When albumin is reduced, a greater proportion of total drug exists in the unbound state. At the same total measured concentration, the free — and therefore active — drug concentration is higher than in a patient with normal albumin. For a narrow therapeutic index drug like digoxin, this shift in free fraction can be sufficient to produce toxicity even when the total concentration appears within the reference range. This is a clinically important limitation of therapeutic drug monitoring when protein binding is abnormal: the measured total concentration may be misleading.